ライフサイエンスコーパス: acetonide

1 le to conversion to glycal 22 via the chloro acetonide.

2 effect on the cytotoxicity of triamcinolone acetonide.

3 olenic acid, 11-HLA) from (R)-glyceraldehyde acetonide.

4 e alone or in combination with triamcinolone acetonide.

5 ghtly long-lasting effect than triamcinolone acetonide.

6 roids such as dexamethasone and fluocinolone acetonide.

7 ed with ciprofloxacin, 0.3%, or fluocinolone acetonide, 0.025%, otic solution alone.

8 Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious

9 Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution was efficacious and saf

10 rity vs ciprofloxacin, 0.3%, or fluocinolone acetonide, 0.025%, otic solutions alone in the main stud

11 who were treated with inhaled triamcinolone acetonide (100 microg per puff).

12 thiophene, subsequent generation of the keto acetonide 12 followed by its Meerwein-Ponndorf-Verley re

13 emonstrated that panaxytriol and panaxytriol acetonide (12) moderately suppress tumor growth with lit

14 bizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were reviewed for 2465

15 duction of the ester and by formation of the acetonides 13bcd.

16 one (1), dexamethasone (4), and fluocinolone acetonide (2).

17 RPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without the vehicle was

18 The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehicle also had a

19 per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and 4 in 5386 for

20 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes

21 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes

22 perones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the receptor as GR.hs

23 ted to receive an injection of triamcinolone acetonide, 40 mg, either IM in the ipsilateral ventroglu

24 riod of treatment with inhaled triamcinolone acetonide (400 microg twice per day).

25 They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice daily.

26 d by ester reduction and by formation of the acetonides 7bc.

27 Subjects were stabilized on triamcinolane acetonide (800 microg daily) and then enrolled in a 2-wk

28 synthesis of orthogonally protected Fmoc-Dyp-acetonide (9) and of several Fmoc-d-Hot horizontal lineT

29 18) derived from N-Boc-L-serine methyl ester acetonide (9), affording two novel ceramide analogues, (

30 in fact, engagement of the C9-C10 diol as an acetonide actually leads to notably enhanced cytotoxicit

31 on's retrobulbar injections of triamcinolone acetonide after explaining the procedure and acquiring c

32 Cyanohydrin acetonide alkylations were used to assemble the carbon s

33 re effective than intravitreal triamcinolone acetonide alone.

34 therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorticoid, greatly

35 ticular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine hydrochloride, or BCT pl

36 only in substrates that contain both a trans-acetonide and a tertiary amide substituent at C2.

37 of a 1,2-acetonide in the presence of a 1,3-acetonide and an (E)-selective olefination of an unstabl

38 Removal of acetonide and benzyl protecting groups afforded pure tri

39 I)-catalyzed reactions of (R)-glyceraldehyde acetonide and dibenzylamine with terminal alkynes provid

40 proved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients by using infr

41 Intravitreal triamcinolone acetonide and the IDI were superior to PTA for treating

42 ed albuterol and intramuscular triamcinolone acetonide and yearly for 5 years.

43 ailored Rychnovsky alkylation of cyanohydrin acetonides and elaborate Krische couplings to set the ch

44 ds (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) ranged from 0.2 to

45 , chemical transformation into ecdysone 2, 3-acetonide, and mass spectrometry.

46 articles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subconjunctival inje

47 ps (43% overall yield) from D-glyceraldehyde acetonide, and the cyclopentenone (+)-14, prepared in on

48 asone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to treat chronic

49 Using glyceraldehyde acetonide as a chiral-pool precursor, an enantioselectiv

50 by intraoperative findings of triamcinolone acetonide-assisted pars plana vitrectomy (PPV).

51 ds; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cromolyn sodium;

52 se to a characterizing dose of triamcinolone acetonide (B, -8.4 mL/1% change FEV(1) posttriamcinolone

53 coids (triamcinolone acetonide, fluocinolone acetonide, clobetasol propionate, and fluticasone propio

54 nated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively taken up by th

55 Acetonide-containing benzannulated nonatrienones resulte

56 losing olefin metatheses converted them into acetonide-containing benzocycloheptadienones.

57 baseline, after intramuscular (triamcinolone acetonide) corticosteroid treatment, and at 1- and 3-yea

58 ed crystallinity compared to their five-ring acetonide counterparts.

59 The effects of triamcinolone acetonide cream 0.025% were assessed based on gene expre

60 Late-stage acetonide deprotection challenges were overcome by A rin

61 The acetonide deprotection protocol described herein is expe

62 Final reductive amination and acetonide deprotection provided compounds 14 and 15 from

63 a high yielding, acid-mediated simultaneous acetonide deprotection-dithiane removal-ketalization pro

64 of DFT calculations, and the preparation of acetonide derivative 7a.

65 lute stereochemistry was determined on a bis-acetonide derivative using the variable temperature Mosh

66 adducts were confirmed by NMR analysis of 12 acetonide derivatives prepared from the corresponding 5,

67 Mass spectrometric analysis after acetonide derivatization also revealed that ester format

68 cycloaddition of cyclopent-2-en-1-one to the acetonide derived from enantiomerically pure and enzymat

69 ch has an altered affinity for triamcinolone acetonide, dexamethasone, and corticosterone.

70 nd TMPRSS2, but treatment with triamcinolone acetonide did not decrease expression of either gene.

71 tudy compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Tenon's injectio

72 Treatment with topical triamcinolone acetonide dramatically reduced pathology but increased v

73 easible to construct a nontoxic fluocinolone acetonide drug delivery device that reproducibly release

74 The fluocinolone acetonide drug pellet can dislocate spontaneously from t

75 beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run-in period wer

76 rticular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage los

77 c application of glucocorticoid fluocinolone acetonide (FA).

78 al-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabeti

79 To investigate the effects of fluocinolone acetonide (FAc) on the progression to proliferative diab

80 able poly-L-glutamic acid (PGA)-fluocinolone acetonide (FLUO) conjugate that allows the controlled re

81 our synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobetasol propionate

82 Intravitreal triamcinolone acetonide followed by laser may be more effective than i

83 suspension releasing 5-FU and triamcinolone acetonide for 1 month.

84 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.

85 mparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study.

86 mical modifications, including methanolysis, acetonide formation, and application of the modified Mos

87 o-step NMO-promoted osmylations bracketed by acetonide formation, and wholesale deprotection.

88 y of suprachoroidally injected triamcinolone acetonide formulation (CLS-TA), a suspension of triamcin

89 predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's space to the ex

90 protection of both terminal and internal N,0-acetonide functionalities.

91 o a cytosine aldehyde protected as the 2',3'-acetonide gave predominately the 5'R isomer, while phosp

92 In the triamcinolone acetonide group, 12 months after surgery the amplitude o

93 D-Glyceraldehyde acetonide has been used as the starting point for access

94 verse event associated with the fluocinolone acetonide implant (FAI), but no data are available regar

95 Sustained-release fluocinolone acetonide implant (Retisert) dissociation is a common oc

96 Twenty-seven sustained-release fluocinolone acetonide implant (Retisert) exchange or removal surgeri

97 7 consecutive sustained-release fluocinolone acetonide implant (Retisert) exchanges or removals betwe

98 Visual outcomes of fluocinolone acetonide implant and systemic treatment for intermediat

99 Fluocinolone acetonide implant improved the BCVA, reduced the CRT, an

100 s with uveitis treated with the fluocinolone acetonide implant or standard systemic therapy.

101 surgically placed intravitreous fluocinolone acetonide implant or systemic corticosteroids supplement

102 that 75% of eyes receiving the fluocinolone acetonide implant required intraocular pressure (IOP) lo

103 These results suggest that fluocinolone acetonide implant therapy is associated with a clinicall

104 Fluocinolone acetonide implant therapy was associated with a greater

105 Fluocinolone acetonide implant therapy was reasonably cost-effective

106 munosuppression or intravitreal fluocinolone acetonide implant therapy.

107 rognosis with both systemic and fluocinolone acetonide implant treatment.

108 omized clinical trial comparing fluocinolone acetonide implant vs systemic corticosteroids and immuno

109 sociation between intravitreous fluocinolone acetonide implant vs systemic therapy and long-term visu

110 York, USA), a nonbiodegradable fluocinolone acetonide implant, was approved for use in noninfectious

111 than time to exchange of intact fluocinolone acetonide implants (70.5 vs 44.9 months; P < .001).

112 ] (aHR, 2.58); and prior use of fluocinolone acetonide implants (aHR, 9.75).

113 Fluocinolone acetonide implants can be considered, but have a high ri

114 intravitreal dexamethasone and fluocinolone acetonide implants or inserts in noninfectious uveitic m

115 mend that patients treated with fluocinolone acetonide implants receive frequent IOP monitoring and r

116 rds of 224 patients in whom 407 fluocinolone acetonide implants were placed by either of 2 surgeons b

117 Of 77 exchanged fluocinolone acetonide implants without dislocated pellets, 11 (14.2%

118 omized to receive intravitreous fluocinolone acetonide implants.

119 vice that reproducibly releases fluocinolone acetonide in a linear manner over an extended period.

120 ly released the corticosteroid triamcinolone acetonide in a rat model of patellar tendon injury, redu

121 g sesquiterpene (-)-alpha-cedrene yields the acetonide in an overall yield <20%.

122 I (Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for

123 y scale (DRSS) grade during the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase

124 l injections of bevacizumab or triamcinolone acetonide in patients with macular edema and cataract is

125 ctions are a selective deprotection of a 1,2-acetonide in the presence of a 1,3-acetonide and an (E)-

126 uccessfully converted into the corresponding acetonides in up to 92% yield and their olfactive proper

127 tone to prepare 2,2-dimethyl-1,3-dioxolanes (acetonides) in good to excellent yields.

128 tion (CLS-TA), a suspension of triamcinolone acetonide, in improving vision among patients with nonin

129 In contrast, triamcinolone acetonide-induced luciferase activity was maximal at a d

130 ng suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA), in eyes with m

131 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (

132 (proprietary formulation of a triamcinolone acetonide injectable suspension), and 64 received sham,

133 study showed that intravitreal triamcinolone acetonide injection and the dexamethasone intravitreal i

134 injection compared to subtenon triamcinolone acetonide injection at cataract operation.

135 superior to that of periocular triamcinolone acetonide injection for these outcomes.

136 coemulsification with subtenon Triamcinolone acetonide injection group and phacoemulsification only g

137 Intraoperative intravitreal triamcinolone acetonide injection induces earlier and marked exudative

138 tocoagulation and intravitreal triamcinolone acetonide injection resulted in a complete resolution of

139 Intravitreal triamcinolone acetonide injection therapy, in particular the 4-mg dose

140 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls without injection.

141 prachoroidal, and intravitreal triamcinolone acetonide injections and intravitreal dexamethasone and

142 cizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexamethasone impla

143 Fluocinolone acetonide insert-treated eyes had significantly reduced

144 neficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supplemental oxygen;

145 A fluocinolone acetonide intravitreal implant (Retisert) was implanted

146 The fluocinolone acetonide intravitreal implant was approved by the Unite

147 Fluocinolone acetonide intravitreal implants are an effective therapy

148 Triamcinolone acetonide is toxic to proliferating cells of retinal ori

149 kness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edema secondary to

150 y of intravitreal injection of triamcinolone acetonide IVTA combined with standard phacoemulsificatio

151 Intravitreal triamcinolone acetonide (IVTA) is an effective treatment for recalcitr

152 Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing macular edema

153 In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 weeks prior to th

154 e plate, and 20 mg of subtenon triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) was injected o

155 tive photochemical sp(3) C-H fluorination of acetonide ketals that presents interesting problems in c

156 iodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated and nasally admi

157 ior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted vitreous and

158 eoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreous, and choroi

159 hydrate based oxepine that uses 2,3;4,6-di-O-acetonide mannose as a key starting material.

160 such as trans-retinoic acid and fluocinolone acetonide, markedly inhibit both 12-O-tetradecanoylphorb

161 llen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month).

162 Intravitreal triamcinolone acetonide may be more effective than laser.

163 ons of ranibizumab or subtenon triamcinolone acetonide may prevent further progression in CMT in indi

164 Hydrolysis of the acetonide moiety of 41, followed by oxidative cleavage o

165 injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexacetonide [n = 7]

166 ed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (Asthma Control

167 resent method was also extended to deprotect acetonides obtained from 1,2-, and 1,3-terminal diols.

168 ffect spectroscopy, the crystal structure of acetonide of 1,3-diol analogue 3ai, and further density

169 zolide 11b which, upon coupling with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide ad

170 with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide adenine dinucleotide (15) in 94%

171 The tricyclic acetonide of the dipeptide d-Hot horizontal lineTap is r

172 The acetonide of the protected amino acid cis-dihydroxyproli

173 ted cyclobutane was synthesized from the bis(acetonide) of d-glucose using dicyclopentadienylzirconiu

174 M peeling assisted with either triamcinolone acetonide or infracyanine green staining improves visual

175 al growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies.

176 Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral protein kinase C

177 cyclization reaction taking advantage of the acetonide pendant group.

178 Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard ratio [HR], 0.7

179 s (30 g) scales for the synthesis of C3'/C5'-acetonide protected uridine.

180 he addition of vinyllithium reagent 7 to the acetonide-protected aldehyde 8 to access the carbon back

181 -pyranosylations employing easily accessible acetonide-protected donors.

182 ohex-2-ene-1-one (3) has been developed from acetonide-protected meso-1,2-dihydrocatechol derivative

183 diol-based subunits were prepared from their acetonide-protected precursors (1a-4a).

184 A lithium enolate derived from an acetonide-protected pyroglutaminol undergoes a highly se

185 ance, accommodating ester, ether, silyl, and acetonide protecting groups.

186 doglycals bearing ester, ether, silicon, and acetonide protection were synthesized in good to excelle

187 ME2 and 2-methoxyestradiol-15 alpha,16 alpha-acetonide, provided 29.4% and 26.7% inhibition of tumor

188 age of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 months preceding i

189 LH/HWE ester homologation as well as a novel acetonide rearrangement/glycal formation cascade.

190 cy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intravitreal bevacizumab (IVB) int

191 of suprachoroidal injection of triamcinolone acetonide (SCTA) using a modified custom needle with top

192 Fluocinolone acetonide slow release implant (Iluvien(R)) was approved

193 However, triamcinolone acetonide staining is associated with an increase of fER

194 ssignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 sessions of manual ph

195 advantages of investigational triamcinolone acetonide suspension (CLS-TA; Clearside Biomedical, Alph

196 Sedimentation of 1.0 mL triamcinolone acetonide suspension for intravitreal use after 3 min of

197 conjunctival injection of 2 mg triamcinolone acetonide (TA) alone.

198 with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small heterodimer p

199 ansscleral drug delivery using triamcinolone acetonide (TA) as a model drug.

200 safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique.

201 GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transactivation of t

202 suprachoroidal placement of a triamcinolone acetonide (TA) suspension.

203 of suprachoroidal injection of Triamcinolone Acetonide (TA) using a microinjector as a mono-treatment

204 tralesional multi-injection of triamcinolone acetonide (TA) using a syringe is one of the most common

205 ugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using glutaric acid as a

206 examethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize proinflammatory s

207 nts-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial tears (LBAT)-

208 and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors of a corticos

209 orticosteroid (TCS) treatment, triamcinolone acetonide (TA), on the formation, maintenance and reacti

210 00 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.

211 GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.

212 electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were exploited for

213 Triamcinolone acetonide (TAA) is an anti-inflammatory steroid used for

214 Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatments employed t

215 g, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 microg, H: 1,600 m

216 the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ionization mass s

217 to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma following suprachoroi

218 Ireland-Claisen rearrangement using a chiral acetonide that serves as internal stereocontrol element

219 Triamcinolone acetonide, the most commonly used intravitreal corticost

220 olipid analogues from D-mannitol 1,2:5,6-bis-acetonide to give two 1,1-difluorodeoxy analogues of (2R

221 a subconjunctival injection of triamcinolone acetonide to one eye.

222 ncapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneously in rats b

223 was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).

224 ented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal bevacizumab-t

225 e-treatment with INCS (220 mug triamcinolone acetonide twice daily).

226 Fluocinolone acetonide was a helpful adjunct for the treatment of chr

227 In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD at the femoral

228 Carbon-11-labeled triamcinolone acetonide was formulated as the commercial product, and

229 th the vehicle alone, in which triamcinolone acetonide was suspended.

230 e P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced dose-dependent i

231 derate potency steroids such as fluocinolone acetonide were inactive.

232 of a synthetic corticosteroid, fluocinolone acetonide, were constructed.

233 diate for the synthesis of the corresponding acetonide, which is an extremely powerful semisynthetic

234 ma in response to intravitreal triamcinolone acetonide will be reviewed.

235 ve Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in Subjects with

236 laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.

237 he R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for 24 hours (P <

238 nd R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 24 hours was 70

239 Triamcinolone acetonide with vehicle caused a greater reduction in cel

240 9 cells when treated with both triamcinolone acetonide, with or without the vehicle at a concentratio

241 erwent periocular injection of triamcinolone acetonide, with resolution of the subretinal fluid.

242 ase activity when treated with triamcinolone acetonide without the vehicle at any of the doses, but t